Imeglimin, a novel antidiabetic drug synthesized from metformin, attenuates knee osteoarthritis development and progression through AMPK activation and NF-κB signaling inhibition
Publication date: Available online 20 November 2025
Source: Osteoarthritis and Cartilage
Author(s): Yuki Hyodo, Yukio Akasaki, Ichiro Kurakazu, Masanari Kuwahara, Taisuke Uchida, Ryota Hirose, Mamiko Sakai, Takumi Kita, Koki Kato, Yasuharu Nakashima